Gestenorone capronate(Depostat)による前立腺肥大症の治療

概要

論文の詳細を見る
l7-hydroxy-19-norprogesterone caproate (Depostat) was administered to a total of 24 patients (average age of 69.2) comprising 20 patients with stage II of prostatic hypertrophy and 4 patients with stage III. Depostat was injected in all patients into the gluteal muscle at a dosage of 200 mg once every week for 12 weeks (12 times) consecutively (total dosage of 2,400 mg). 1) Subjective symptoms were alleviated in 54% of the patients. Especially, the alleviation was observed in 65% of the patients with stage II of prostatic hypertrophy. 2) The decreases in the frequency of urination/day and in residual urinary volume were observed in 75% and 60% of the patients respectively. These decreases were significant in a statistical analysis. 3) The decrease observed in the prostatic weight which was measured by Thumann's method was significant in a statistical analysis. 4) There were no serious side effects. However, mild fever was observed in 2 cases and there was significant decrease of hematocrit value in a statistical analysis, but the changes were within the normal range.
泌尿器科紀要刊行会の論文